WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

Search

Hims & Hers Health Inc

Chiusa

SettoreConsumatore difensivo

31.15 0.48

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.94

Massimo

31.21

Metriche Chiave

By Trading Economics

Entrata

-50M

26M

Vendite

80M

481M

P/E

Media del settore

54.722

44.466

EPS

0.227

Margine di Profitto

5.409

Dipendenti

1,637

EBITDA

-8.2M

19M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+49.76% upside

Dividendi

By Dow Jones

Utili prossimi

5 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-4.7B

6.5B

Apertura precedente

30.67

Chiusura precedente

31.15

Notizie sul Sentiment di mercato

By Acuity

18%

82%

9 / 152 Classifica in Consumer defensive

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Hims & Hers Health Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 apr 2025, 23:15 UTC

I principali Market Mover

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 feb 2025, 15:33 UTC

I principali Market Mover

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 nov 2024, 19:07 UTC

I principali Market Mover

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 ott 2024, 15:02 UTC

I principali Market Mover

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 ott 2024, 11:28 UTC

I principali Market Mover

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2 apr 2025, 16:53 UTC

Notizie principali

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 mar 2025, 15:54 UTC

Notizie principali

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 feb 2025, 23:20 UTC

Utili

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 feb 2025, 12:00 UTC

Notizie principali

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 dic 2024, 17:16 UTC

Notizie principali

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 dic 2024, 15:14 UTC

Notizie principali

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 dic 2024, 15:02 UTC

Notizie principali

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 dic 2024, 13:47 UTC

Notizie principali

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 dic 2024, 07:00 UTC

Notizie principali

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 ott 2024, 14:45 UTC

Notizie principali

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 ott 2024, 13:12 UTC

Notizie principali

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 ott 2024, 11:45 UTC

Notizie principali

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 ott 2024, 10:14 UTC

Notizie principali

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 ago 2024, 17:52 UTC

Acquisizioni, Fusioni, Takeovers

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 giu 2024, 11:00 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 mag 2024, 20:37 UTC

Utili

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Confronto tra pari

Modifica del prezzo

Hims & Hers Health Inc Previsione

Obiettivo di Prezzo

By TipRanks

49.76% in crescita

Previsioni per 12 mesi

Media 46.5 USD  49.76%

Alto 85 USD

Basso 21 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hims & Hers Health Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

13 ratings

5

Acquista

6

Mantieni

2

Vendi

Punteggio Tecnico

By Trading Central

31.0237 / 31.88Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bullish Evidence

Sentiment

By Acuity

9 / 152 Classifica in Consumatore difensivo

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.